Alfi (ALFIW) Competitors

$0.0002
0.00 (0.00%)
(As of 04/26/2024 ET)

ALFIW vs. BTX, CIDM, and NLOK

Should you be buying Alfi stock or one of its competitors? The main competitors of Alfi include Brooklyn ImmunoTherapeutics (BTX), Cinedigm (CIDM), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.

Alfi vs.

Alfi (NASDAQ:ALFIW) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both information companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Company Net Margins Return on Equity Return on Assets
AlfiN/A N/A N/A
Brooklyn ImmunoTherapeutics N/A N/A N/A

Alfi and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
AlfiN/AN/A
Brooklyn ImmunoTherapeuticsOutperform Votes
No Votes
Underperform Votes
69
100.00%

26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 20.5% of Brooklyn ImmunoTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alfi$200.68KN/AN/AN/AN/A
Brooklyn ImmunoTherapeuticsN/AN/AN/A-$2.27-0.79

In the previous week, Brooklyn ImmunoTherapeutics had 1 more articles in the media than Alfi. MarketBeat recorded 1 mentions for Brooklyn ImmunoTherapeutics and 0 mentions for Alfi. Brooklyn ImmunoTherapeutics' average media sentiment score of 0.30 beat Alfi's score of 0.00 indicating that Brooklyn ImmunoTherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alfi Neutral
Brooklyn ImmunoTherapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alfi
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Brooklyn ImmunoTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Brooklyn ImmunoTherapeutics beats Alfi on 4 of the 5 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALFIW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALFIW vs. The Competition

MetricAlfiSoftware Publishers IndustryInformation SectorNASDAQ Exchange
Market CapN/AN/A$3.02B$7.63B
Dividend YieldN/AN/A3.69%3.94%
P/E RatioN/AN/A6.8518.08
Price / SalesN/AN/A3.1682.65
Price / CashN/AN/AN/A35.09
Price / BookN/AN/AN/A4.38
Net IncomeN/AN/AN/A$214.23M
7 Day PerformanceN/AN/A-5.77%1.85%
1 Month PerformanceN/AN/A-8.62%-3.74%
1 Year PerformanceN/AN/A-6.79%9.24%

Alfi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTX
Brooklyn ImmunoTherapeutics
0 of 5 stars
$1.96
-8.4%
N/A-46.1%$115.30MN/A-0.86N/A
CIDM
Cinedigm
0 of 5 stars
$0.95
-16.7%
N/AN/A$177.57M$72.33M-19.00140
NLOK
NortonLifeLock
0 of 5 stars
$20.68
+0.9%
N/A+17.2%$11.82B$2.82B14.46N/A

Related Companies and Tools

This page (NASDAQ:ALFIW) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners